Twist's revenues were $31.2 million for the quarter, up 62% for the quarter compared to $19.3 million for the same period last year. The company posted a net loss for the quarter of $37.9 million, compared with a net loss of $31.8 million the same period of 2020. The company cited net loss as increased investments in commercial organization and research and development activities.

Total orders received for the quarter were $41.7 million, compared to $24.6 million for the same period of the 2020 fiscal year.

Company leaders credit the revenue growth to the company signing new biopharma partnerships with multiple associated programs and increasing density for its data storage vertical market.

Twist, Vivlion to generate gRNA libraries for CRISPR applications
Twist Bioscience and Vivlion are collaborating to generate guide RNA (gRNA) libraries for CRISPR genome engineering applications and target discovery...

Pure Biologics, Twist partner on immuno-oncology drugs
Pure Biologics and Twist Bioscience have partnered to accelerate the discovery of antibody-based immuno-oncology drugs.

Twist Bioscience purchases library designed with Distributed Bio
Twist Bioscience plans to exercise its option to purchase all rights to a G-coupled protein receptor library and its Twist antibody optimization software,...

Stanford gains access to Twist's 'library of libraries'
Twist Bioscience has granted Stanford University access to its antibody discovery and optimization services and its "library of libraries" for biologics...

Twist, Kyowa Kirin partner on antibody discovery
Twist Bioscience has inked a deal with pharmaceutical company Kyowa Kirin Pharmaceutical Research to develop novel antibodies for therapeutic use against...